Physician profile
Tamara Granner
NPI 1811419237
$3,156.57
in general payments reported to CMS, 2019-2025
12 companies · $797 in 2025
The $797 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $47.95 · 2021: $377 · 2022: $432 · 2023: $177 · 2024: $1,067 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $499.93 | 2020-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $472.49 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $457.70 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $388.41 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $373.85 | 2022-2024 | Infuse, Vyzulta, Miebo |
| Glaukos Corporation | $305.53 | 2024-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Oyster Point Pharma, INC. | $136.18 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $132.53 | 2019-2022 | |
| Alcon Vision LLC | $126.15 | 2019 | |
| Coopervision INC. | $126.09 | 2024 | Myday Contact Lens, Clariti Contact Lens |
| Allergan, INC. | $100.64 | 2022 | |
| Shire North American Group INC | $37.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Granner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.